In a publish-hoc prognosis of the CREDENCE survey, there were no security signals when the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (Invokana, Janssen) became once…
In a publish-hoc prognosis of the CREDENCE survey, there were no security signals when the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (Invokana, Janssen) became once…